These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 38957980)

  • 1. Situational prevention: Pharmacotherapy during periods of increased risk for migraine attacks.
    Lipton RB; Ailani J; Mullin K; Pavlovic JM; Tepper SJ; Dodick DW; Blumenfeld AM
    Headache; 2024; 64(7):859-864. PubMed ID: 38957980
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy, tolerability, and safety of eptinezumab in patients with a dual diagnosis of chronic migraine and medication-overuse headache: Subgroup analysis of PROMISE-2.
    Diener HC; Marmura MJ; Tepper SJ; Cowan R; Starling AJ; Diamond ML; Hirman J; Mehta L; Brevig T; Sperling B; Cady R
    Headache; 2021 Jan; 61(1):125-136. PubMed ID: 33314079
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Gepants, calcitonin-gene-related peptide receptor antagonists: what could be their role in migraine treatment?
    Moreno-Ajona D; Pérez-Rodríguez A; Goadsby PJ
    Curr Opin Neurol; 2020 Jun; 33(3):309-315. PubMed ID: 32251023
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Calcitonin Gene-Related Peptide Receptor Antagonists (Gepants) for the Acute Treatment of Nausea in Episodic Migraine: A Systematic Review and Meta-Analysis.
    Chan TLH; Cowan RP; Woldeamanuel YW
    Headache; 2020 Jul; 60(7):1489-1499. PubMed ID: 32515018
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A Brief Review of Gepants.
    Li D; Abreu J; Tepper SJ
    Curr Pain Headache Rep; 2023 Sep; 27(9):479-488. PubMed ID: 37531032
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Preventive migraine treatment with eptinezumab reduced acute headache medication and headache frequency to below diagnostic thresholds in patients with chronic migraine and medication-overuse headache.
    Marmura MJ; Diener HC; Cowan RP; Tepper SJ; Diamond ML; Starling AJ; Hirman J; Mehta L; Brevig T; Cady R
    Headache; 2021 Oct; 61(9):1421-1431. PubMed ID: 34551130
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Calcitonin gene-related peptide (CGRP)-targeted therapies as preventive and acute treatments for migraine-The monoclonal antibodies and gepants.
    Chiang CC; Schwedt TJ
    Prog Brain Res; 2020; 255():143-170. PubMed ID: 33008505
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Long-term (48 weeks) effectiveness, safety, and tolerability of erenumab in the prevention of high-frequency episodic and chronic migraine in a real world: Results of the EARLY 2 study.
    Barbanti P; Aurilia C; Cevoli S; Egeo G; Fofi L; Messina R; Salerno A; Torelli P; Albanese M; Carnevale A; Bono F; D'Amico D; Filippi M; Altamura C; Vernieri F;
    Headache; 2021 Oct; 61(9):1351-1363. PubMed ID: 34309862
    [TBL] [Abstract][Full Text] [Related]  

  • 9. History and Review of anti-Calcitonin Gene-Related Peptide (CGRP) Therapies: From Translational Research to Treatment.
    Tepper SJ
    Headache; 2018 Nov; 58 Suppl 3():238-275. PubMed ID: 30242830
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Is the right way to go in between? : Rimegepant as needed provides preventive benefit. A comment on: monthly migraine days, tablet utilization, and quality of life associated with rimegepant-post hoc results from an open label safety study (BHV3000-201).
    Gantenbein AR; Kleinschmidt A
    J Headache Pain; 2023 Mar; 24(1):33. PubMed ID: 36997843
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Safety of Rimegepant, an Oral CGRP Receptor Antagonist, Plus CGRP Monoclonal Antibodies for Migraine.
    Berman G; Croop R; Kudrow D; Halverson P; Lovegren M; Thiry AC; Conway CM; Coric V; Lipton RB
    Headache; 2020 Sep; 60(8):1734-1742. PubMed ID: 32799325
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The preclinical discovery and development of atogepant for migraine prophylaxis.
    Baraldi C; Beier D; Martelletti P; Pellesi L
    Expert Opin Drug Discov; 2024 Jul; 19(7):783-788. PubMed ID: 38856039
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Gepants for the treatment of migraine.
    Negro A; Martelletti P
    Expert Opin Investig Drugs; 2019 Jun; 28(6):555-567. PubMed ID: 31081399
    [TBL] [Abstract][Full Text] [Related]  

  • 14. CGRP receptor antagonists (gepants).
    Younis S; Latysheva NV; Danilov AB; Ashina M
    Handb Clin Neurol; 2024; 199():51-66. PubMed ID: 38307667
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Targeting CGRP for the Prevention of Migraine and Cluster Headache: A Narrative Review.
    Yuan H; Spare NM; Silberstein SD
    Headache; 2019 Jul; 59 Suppl 2():20-32. PubMed ID: 31291020
    [TBL] [Abstract][Full Text] [Related]  

  • 16. CGRP - a target for acute therapy in migraine: Clinical data.
    Messina R; Goadsby PJ
    Cephalalgia; 2019 Mar; 39(3):420-427. PubMed ID: 29616830
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Emerging drugs for the preventive treatment of migraine: a review of CGRP monoclonal antibodies and gepants trials.
    Silvestro M; Orologio I; Siciliano M; Trojsi F; Tessitore A; Tedeschi G; Russo A
    Expert Opin Emerg Drugs; 2023 Dec; 28(2):79-96. PubMed ID: 37185047
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Situational prevention in migraine: are we doing the right thing?
    Pellesi L; Martelletti P
    J Headache Pain; 2024 Aug; 25(1):137. PubMed ID: 39174943
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Safety and tolerability of monoclonal antibodies targeting the CGRP pathway and gepants in migraine prevention: A systematic review and network meta-analysis.
    Messina R; Huessler EM; Puledda F; Haghdoost F; Lebedeva ER; Diener HC
    Cephalalgia; 2023 Mar; 43(3):3331024231152169. PubMed ID: 36786548
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Eptinezumab for prevention of chronic migraine: A randomized phase 2b clinical trial.
    Dodick DW; Lipton RB; Silberstein S; Goadsby PJ; Biondi D; Hirman J; Cady R; Smith J
    Cephalalgia; 2019 Aug; 39(9):1075-1085. PubMed ID: 31234642
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.